ID Genomics Develops a Rapid Test to ID COVID Variants
Seattle-based ID Genomics (IDG) has invented a dipstick-based rapid test for simultaneous identification of a large number of genetic variants of SARS-CoV-2 and has just received a National Institutes of Health (NIH) grant to expedite bringing this test to market. The test will concurrently fingerprint known COVID-19 variants of concern or interest including Alpha, Beta, Gamma, Delta, Delta-plus, Epsilon, Lambda, etc., and offers the potential to detect the emergence of novel variants.
The entire test not only can be accomplished in two hours, but will not require expensive instrumentation and can be rapidly deployed across epidemiological surveillance labs worldwide.
“The recent explosive rise in various SARS-CoV-2 mutants, especially those with changes in the Spike protein – the main target of vaccines – is of very significant concern due to the ability of the mutated variants to escape protective antibodies, becoming more transmissible and/or virulent,” said Evgeni Sokurenko, principal investigator, a founder of ID Genomics and a professor of microbiology at the University of Washington, the academic partner on the NIH grant. “Rapid and comprehensive detection of the current and newly emerging viral variants will be invaluable for real-time surveillance of the COVID-19 pandemic and elucidation of the risks of infection in vaccinated, convalescent and non-immunized individuals.”
Lisa Brown has decades of experience in corporate communications and marketing management with organizations including Coldwell Banker Residential, Grubb & Ellis, Marcus & Millichap, NAIOP, SIOR and ALM.
In those positions, she worked in conjunction with chief executive officers and chief marketing officers to create corporate messaging, cohesive branding standards, strategic marketing plans and thought pieces. Brown is a frequent speaker at industry events and an editing adjunct professor for an online course. She has a master’s degree in mass communications from San Jose State University.